[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100635743":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":20,"responsibleParty":27,"collaborators":31,"id":37,"slug":38,"hasResults":39,"nctId":40,"briefTitle":41,"officialTitle":42,"acronym":43,"eligibilityCriteria":44,"healthyVolunteers":39,"sex":45,"minAge":46,"maxAge":47,"enrollmentInfo":48,"targetDuration":20,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":64,"whyStopped":20,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":20},{"fullName":5,"class":6},"Zhejiang Provincial People's Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Experimental: Allogeneic WTX-212C","EXPERIMENTAL","Participants will receive allogeneic WTX-212C via intravenous infusion in dose-escalation and dose-expansion cohorts.",[13],"Drug: allogeneic WTX-212C",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","allogeneic WTX-212C","allogeneic WTX-212C is an investigational allogeneic engineered red blood cell-based injectable product administered intravenously.",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Yang Liu, PhD","CONTACT","8613666601475","Yangliuqq2003@163.com",{"type":28,"investigatorFullName":29,"investigatorTitle":30,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"PRINCIPAL_INVESTIGATOR","Liu Yang","Principal Investigator",[32,35],{"name":33,"class":34},"Westlake Therapeutics","INDUSTRY",{"name":36,"class":6},"First People's Hospital of Hangzhou","100635743","early-phase-1-allogeneic-wtx-212c-in-advanced-solid-tumors-100635743",false,"NCT07556653","Allogeneic WTX-212C in Advanced Solid Tumors","A Multicenter, Open-label, Single-arm Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Allogeneic WTX-212C Engineered Red Blood Cell Injection in Patients With Advanced Solid Tumors","WTX-212C-IIT","Inclusion Criteria:\n\n* Age 18-75 years\n* Histologically or cytologically confirmed advanced solid tumors\n* At least one measurable lesion per RECIST 1.1\n* ECOG performance status ≤1\n* Adequate organ function\n* Life expectancy ≥12 weeks\n\nExclusion Criteria:\n\n* Uncontrolled serious medical conditions\n* Active or uncontrolled infections\n* Symptomatic or unstable CNS metastases\n* History of severe hypersensitivity to biologic agents\n* Autoimmune diseases requiring systemic treatment\n* Prior severe immune-related adverse events\n* Conditions affecting red blood cell integrity","ALL","18 Years","75 Years",{"count":49,"type":50},24,"ESTIMATED","INTERVENTIONAL",[53],"EARLY_PHASE1","This is a multicenter, open-label, single-arm Phase I study to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and preliminary antitumor activity of allogeneic WTX-212C, an investigational allogeneic engineered red blood cell (RBC)-based product, in patients with advanced solid tumors who have failed standard therapies or have no available standard treatment options.\n\nThe study consists of a dose-escalation phase using a 3+3 design followed by a dose-expansion phase. Participants will receive allogeneic WTX-212C via intravenous infusion. Tumor assessments will be performed every 6 weeks according to RECIST 1.1.",[56],"Advanced Solid Tumors",[58,59,60,61,62,63],"Engineered Red Blood Cells","Immunotherapy","Phase I","Solid Tumor","Allogeneic Engineered Red Blood Cell","uRBC","NOT_YET_RECRUITING","2026-04-21",{"date":67,"type":68},"2026-04-29","ACTUAL",{"date":70,"type":50},"2026-04-10",{"date":72,"type":50},"2028-04-09",{"name":5,"class":6}]